 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 6 | 20 | 26 | | 1991 | 12 | 12 | 24 | | 1992 | 6 | 11 | 17 | | 1993 | 3 | 10 | 13 | | 1994 | 4 | 18 | 22 | | 1995 | 6 | 13 | 19 | | 1996 | 4 | 15 | 19 | | 1997 | 3 | 8 | 11 | | 1998 | 1 | 14 | 15 | | 1999 | 7 | 6 | 13 | | 2000 | 7 | 10 | 17 | | 2001 | 12 | 17 | 29 | | 2002 | 7 | 19 | 26 | | 2003 | 10 | 15 | 25 | | 2004 | 13 | 19 | 32 | | 2005 | 19 | 14 | 33 | | 2006 | 17 | 15 | 32 | | 2007 | 26 | 12 | 38 | | 2008 | 17 | 22 | 39 | | 2009 | 36 | 19 | 55 | | 2010 | 30 | 23 | 53 | | 2011 | 15 | 18 | 33 | | 2012 | 14 | 12 | 26 | | 2013 | 12 | 11 | 23 | | 2014 | 33 | 13 | 46 | | 2015 | 13 | 8 | 21 | | 2016 | 20 | 15 | 35 | | 2017 | 23 | 13 | 36 | | 2018 | 25 | 11 | 36 | | 2019 | 13 | 7 | 20 | | 2020 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020 09 14; 9:CD013206.
-
Scott FI. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? Dig Dis Sci. 2020 08; 65(8):2158-2160.
-
Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Dapena Diaz JL, Henry M, De Benedetti F, Grom A, Lapeyre G, Jacqmin P, Ballabio M, de Min C. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020 05 07; 382(19):1811-1822.
-
Powell LA, Fox JM, Kose N, Kim AS, Majedi M, Bombardi R, Carnahan RH, Slaughter JC, Morrison TE, Diamond MS, Crowe JE. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease. PLoS Pathog. 2020 05; 16(5):e1008517.
-
Amaya ML, Jimeno A, Kamdar M. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs Today (Barc). 2020 Apr; 56(4):287-294.
-
Zijlstra LE, Schwartz GG, Steg PG, Jukema JW. Reply: Alirocumab in Polyvascular Atherosclerotic Disease. J Am Coll Cardiol. 2020 01 21; 75(2):241.
-
Hong JP, McCarthy MK, Davenport BJ, Morrison TE, Diamond MS. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody. J Virol. 2019 12 15; 93(24).
-
Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
-
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 01 10; 38(2):155-165.
-
Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 2019 11; 121:177-183.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|